Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Bioprinting Scaffolding Technology Offers Potential for Regenerating Tissue

By LabMedica International staff writers
Posted on 27 Nov 2012
The groundbreaking technology of bioprinting is showing promise in building scaffolds in which to grow cells for regenerative medicine applications.

The study’s findings were published in the November 2012 issue of the journal Science. In the article, Prof. More...
Brian, from the University of Manchester’s (UK) School of Materials assessed the hypothesis of employing printer technology to construct structures in which to grow cells, to help to regenerate tissue.

Both laser printer and inkjet technology can be used to build the three-dimensional (3D) scaffolds that cells can be grown in and also position the cells in these structures simultaneously. Prof. Derby clarified how bioprinting works, “Inkjet technology places the structure’s material in small droplets, which then solidify. More droplets are then placed on top of the previous ones in a specific pattern. The structure is built using this method that is generally referred to as additive manufacture. Laser printing uses light to solidify the structure’s substance layer upon layer. These methods have allowed us to develop very complex scaffolds which better mimic the conditions inside the body.”

The scaffold provides a surface for the cells to adhere, multiply, and flourish. Both the scaffold substance, composition, and its internal structure regulate the behavior and health of the cells inside. In his review article, Prof. Derby examined research where porous structures have been constructed through bioprinting. They are then positioned in the body to help act as a scaffold to encourage cell growth. The cells colonize the structure and it either dissolves or becomes part of the body. This type of treatment can help patients suffering from ailments such as cavity wounds. Clinical trials are ongoing worldwide to refine this technology, and according to Prof. Derby, it is moving towards becoming an established form of science.

Prof. Derby also studied how stem cells are being grown in printed structures that have been permeated with specific chemicals. The chemicals are inserted during the printing process and can determine the type of cell into which the stem cells develop. Stem cells, for instance, could be programmed to become cells that comprise cartilage or bone tissue.

However, there are drawbacks to the technology that is holding back advances such as the capability to grow a complete organ. Study findings have revealed that it is very challenging to actually print the cells at the same time as making the structure that will hold them. The stress on the cell as it goes through both the inkjet and laser process can injure the cell membrane. Cell survival rates have also been variable, ranging from between 40%-95%.

The technology is also a ways from being a research platform to clinical practice. Whereas scaffolds are being clinically trialed, essentially transplanting cells grown in an external structure into a patient is a more sophisticated process. It is still not possible at present to assure a consistent quality, which is required by medical device regulations.

However, studies are being conducted to grow external cells into tissue, such as a skin patch, and transplant that into a patient. Prof. Derby is currently working with ear, nose, and throat surgeons at the Manchester Royal Infirmary. He wants to use bioprinting to print cells without using a scaffold. The printed cells form a sheet that can be used for grafts inside the body, for example, in the nose or mouth.

Prof. Derby said, “It is very difficult to transplant even a small patch of tissue to repair the inside of the nose or mouth. Current practice, to transplant the patient’s skin to these areas, is regarded as unsatisfactory because the transplants do not possess mucous generating cells or salivary glands. We are working on techniques to print sheets of cells that are suitable for implantation in the mouth and nose.”

An area that Prof. Derby foresees is the ability to grow structures that can mimic cancerous tumors. These could then be used to evaluate new drugs, which it is hoped will further the search for more effective treatments. Prof. Derby concluded that there is a strong future for bioprinting and while growing organs is still quite a ways off, these recent developments are very encouraging.

Related Links:
University of Manchester



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
HPV Test
Allplex HPV28 Detection
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.